Global Budesonide Inhaler Market Analysis By Segmentations, Top Key Players, Geographical Expansion, Future Development & Forecast 2024-2035
- PUBLISHED ON
- 1/12/2023
- NO OF PAGES
- 252
- CATEGORY
- Healthcare & Life Sciences
Overview
Budesonide inhaler is a type of medication used for the treatment of asthma and chronic obstructive pulmonary disease (COPD). It belongs to the class of drugs called corticosteroids and is known for its anti-inflammatory properties.
The global budesonide inhaler market is expected to grow in the coming years due to the increasing prevalence of asthma and COPD worldwide. According to the World Health Organization (WHO), around 235 million people suffer from asthma worldwide, and the number is expected to increase in the coming years.
The market is also driven by the increasing adoption of budesonide inhalers as a first-line treatment for asthma and COPD, owing to their effectiveness and safety profile. Additionally, the availability of generic versions of budesonide inhalers has made the medication more affordable and accessible to a larger population.
The market is dominated by key players such as AstraZeneca, Teva Pharmaceutical Industries Ltd., Mylan N.V., and Cipla Limited. These companies are actively involved in product development, partnerships, and collaborations to expand their market presence.
However, the market also faces challenges such as the availability of alternative treatment options and the adverse effects associated with long-term use of corticosteroids. These factors may hinder the growth of the budesonide inhaler market in the coming years.
Overall, the budesonide inhaler market is expected to grow in the coming years due to the increasing prevalence of asthma and COPD and the rising adoption of budesonide inhalers as a first-line treatment option.
Segment Overview
The market segment for budesonide inhalers is primarily focused on respiratory diseases such as asthma and chronic obstructive pulmonary disease (COPD). Budesonide is a corticosteroid medication that helps reduce inflammation in the airways, making it easier for people with respiratory conditions to breathe.
Within the market segment for budesonide inhalers, there may be further subdivisions based on factors such as dosage strength, delivery mechanism, and brand. For example, budesonide inhalers may come in different strengths, such as 90 mcg or 180 mcg per puff. Delivery mechanisms may include traditional metered-dose inhalers (MDIs), dry powder inhalers (DPIs), or nebulizers. Additionally, different pharmaceutical companies may market their budesonide inhalers under different brand names, which may appeal to different subsets of patients based on factors such as cost, convenience, or perceived effectiveness.
The budesonide inhaler market can be segmented based on various factors, including:
1. Indication: Budesonide inhalers are primarily used for the treatment of asthma and chronic obstructive pulmonary disease (COPD). Therefore, the market can be segmented based on the indication for which the inhaler is prescribed.
2. Distribution channel: Budesonide inhalers can be sold through various distribution channels, such as hospital pharmacies, retail pharmacies.
Geographical Overview
The market for budesonide inhalers is global, as it is a widely used medication for the treatment of asthma and chronic obstructive pulmonary disease (COPD) worldwide. However, the market may vary in terms of market size, market growth, and market share depending on the geographic region.
Some of the major regions for the budesonide inhaler market include North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa.
North America and Europe are currently the largest markets for budesonide inhalers due to the high prevalence of asthma and COPD in these regions. However, the market is expected to grow rapidly in Asia Pacific due to the increasing incidence of respiratory disorders and the growing awareness of the benefits of using inhalers.
Latin America and the Middle East and Africa are also expected to experience significant growth in the budesonide inhaler market due to the increasing prevalence of respiratory diseases in these regions.
Overall, the budesonide inhaler market is expected to continue growing due to the increasing incidence of respiratory diseases worldwide and the growing awareness of the benefits of using inhalers for their treatment.
COVID Impact
Budesonide inhalers are primarily used to treat asthma and chronic obstructive pulmonary disease (COPD), which can cause inflammation and narrowing of the airways in the lungs. With the outbreak of COVID-19, there has been a significant impact on the budesonide inhaler market due to its potential use in the treatment of COVID-19 patients.
Several studies have shown that budesonide inhalers can reduce the severity of COVID-19 symptoms, especially in patients with mild or moderate disease. The drug has anti-inflammatory properties that can reduce lung inflammation and improve respiratory function. As a result, there has been an increased demand for budesonide inhalers during the pandemic.
However, the COVID-19 pandemic has also had a negative impact on the budesonide inhaler market due to disruptions in the global supply chain. Many countries have imposed restrictions on the export and import of pharmaceutical products, which has led to shortages of budesonide inhalers in some regions. Moreover, the pandemic has also led to disruptions in the production and distribution of budesonide inhalers, which has further affected the market.
Despite these challenges, the budesonide inhaler market is expected to grow in the coming years, primarily due to the increasing prevalence of respiratory diseases such as asthma and COPD. Additionally, the potential use of budesonide inhalers in the treatment of COVID-19 is likely to drive demand for the drug in the short term.
Competitive Analysis
Budesonide inhalers are a common treatment for asthma and other respiratory conditions. There are several companies that manufacture and market budesonide inhalers, and the market is quite competitive. Here is a brief competitive analysis of the budesonide inhaler market:
1. AstraZeneca: AstraZeneca is one of the leading manufacturers of budesonide inhalers. Their brand name product is Pulmicort, which is available in both a turbuhaler and a respules form. AstraZeneca has a strong presence in the budesonide inhaler market, and their products are widely used by patients and healthcare providers.
2. Teva: Teva is another major player in the budesonide inhaler market. They manufacture a generic version of Pulmicort called Budesonide Inhalation Suspension. Teva has a strong presence in the generic pharmaceuticals market, and their budesonide inhaler is a popular choice for patients and healthcare providers looking for a lower-cost alternative to brand name products.
3. Cipla: Cipla is an Indian pharmaceutical company that produces a budesonide inhaler called Foracort. Foracort is available in both a metered-dose inhaler and a rotacap form. Cipla has a strong presence in the Indian market, and their budesonide inhaler is widely used in that region.
4. Sandoz: Sandoz is a subsidiary of Novartis that produces a generic version of Pulmicort called Budesonide Inhalation Suspension. Sandoz has a strong presence in the generic pharmaceuticals market, and their budesonide inhaler is a popular choice for patients and healthcare providers looking for a lower-cost alternative to brand name products.
5. Lupin: Lupin is an Indian pharmaceutical company that produces a budesonide inhaler called Budecort. Budecort is available in both a metered-dose inhaler and a rotacap form. Lupin has a strong presence in the Indian market, and their budesonide inhaler is widely used in that region.
Overall, the budesonide inhaler market is highly competitive, with several major players vying for market share. AstraZeneca and Teva are the two largest manufacturers of budesonide inhalers, but there are also several smaller companies, such as Cipla, Sandoz, and Lupin, that produce generic versions of the drug. The market is expected to continue to grow as the prevalence of respiratory conditions such as asthma continues to increase.
Global Budesonide Inhaler Market: Regional AnalysisThe countries covered in the regional analysis of the Global Budesonide Inhaler market report are U.S., Canada, and Mexico in North America, Germany, France, U.K., Russia, Italy, Spain, Turkey, Netherlands, Switzerland, Belgium, and Rest of Europe in Europe, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, China, Japan, India, South Korea, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), and Argentina, Brazil, and Rest of South America as part of South America.
Key Benefits:
• The analysis provides an overview of the factors driving and limiting the growth of the market including trends, structure and others.
• Market estimation for type and geographic segments is derived from the current market scenario and expected market trends.
• Porter’s Five Force Model and SWOT analysis are used to study the global Budesonide Inhaler market and would help stakeholders make strategic decisions.
• The analysis assists in understanding the strategies adopted by the companies for the growth of this market.
• In-depth analysis of the types of Budesonide Inhaler would help in identifying future applications in this market.
Reasons to Purchase this Report:
• Qualitative and quantitative analysis of the market based on segmentation involving both economic as well as non-economic factors
• Provision of market value (USD Billion) data for each segment and sub-segment
• Indicates the region and segment that is expected to witness the fastest growth as well as to dominate the market
• Analysis by geography highlighting the consumption of the product/service in the region as well as indicating the factors that are affecting the market within each region
• Competitive landscape which incorporates the market ranking of the major players, along with new service/product launches, partnerships, business expansions, and acquisitions in the past five years of companies profiled
• Extensive company profiles comprising of company overview, company insights, product benchmarking, and SWOT analysis for the major market players
• The current as well as the future market outlook of the industry with respect to recent developments which involve growth opportunities and drivers as well as challenges and restraints of both emerging as well as developed regions
• Includes in-depth analysis of the market of various perspectives through Porter’s five forces analysis
• Provides insight into the market through Value Chain
• Market dynamics scenario, along with growth opportunities of the market in the years to come
• 6-month post-sales analyst support
Objectives of the Study:
• To provide with an exhaustive analysis on the Budesonide Inhaler Market by Product, By Application, By End User and by Region.
• To cater comprehensive information on factors impacting market growth (drivers, restraints, opportunities, and industry-specific restraints)
• To evaluate and forecast micro-markets and the overall market
• To predict the market size, in key regions— North America, Europe, Asia Pacific, Latin America and Middle East and Africa.
• To record and evaluate competitive landscape mapping- product launches, technological advancements, mergers and expansions
Historic Year: 2016-2022
Forecast: 2024-2035
1.1 Study Scope
1.2 Key Market Segments
1.3 Players Covered: Ranking by Budesonide Inhaler Revenue
1.4 Market Analysis by Type
1.4.1 Global Budesonide Inhaler Market Size Growth Rate by Type: 2023 VS 2032
1.4.2 Dry Powder
1.4.3 Suspension
1.4.4 Sprays
1.5 Market by Application
1.5.1 Global Budesonide Inhaler Market Share by Application: 2023-2032
1.5.2 Hospital Pharmacies
1.5.3 Retail Pharmacies
1.5.4 Online Pharmacies
1.6 Study Objectives
1.7 Years Considered
1.8 Overview of Global Budesonide Inhaler Market
1.8.1 Global Budesonide Inhaler Market Status and Outlook (2017-2032)
1.8.2 North America
1.8.3 East Asia
1.8.4 Europe
1.8.5 South Asia
1.8.6 Southeast Asia
1.8.7 Middle East
1.8.8 Africa
1.8.9 Oceania
1.8.10 South America
1.8.11 Rest of the World
2 Market Competition by Manufacturers
2.1 Global Budesonide Inhaler Production Capacity Market Share by Manufacturers (2017-2022)
2.2 Global Budesonide Inhaler Revenue Market Share by Manufacturers (2017-2022)
2.3 Global Budesonide Inhaler Average Price by Manufacturers (2017-2022)
2.4 Manufacturers Budesonide Inhaler Production Sites, Area Served, Product Type
3 Sales by Region
3.1 Global Budesonide Inhaler Sales Volume Market Share by Region (2017-2022)
3.2 Global Budesonide Inhaler Sales Revenue Market Share by Region (2017-2022)
3.3 North America Budesonide Inhaler Sales Volume
3.3.1 North America Budesonide Inhaler Sales Volume Growth Rate (2017-2022)
3.3.2 North America Budesonide Inhaler Sales Volume Capacity, Revenue, Price and Gross Margin (2017-2022)
3.4 East Asia Budesonide Inhaler Sales Volume
3.4.1 East Asia Budesonide Inhaler Sales Volume Growth Rate (2017-2022)
3.4.2 East Asia Budesonide Inhaler Sales Volume Capacity, Revenue, Price and Gross Margin (2017-2022)
3.5 Europe Budesonide Inhaler Sales Volume (2017-2022)
3.5.1 Europe Budesonide Inhaler Sales Volume Growth Rate (2017-2022)
3.5.2 Europe Budesonide Inhaler Sales Volume Capacity, Revenue, Price and Gross Margin (2017-2022)
3.6 South Asia Budesonide Inhaler Sales Volume (2017-2022)
3.6.1 South Asia Budesonide Inhaler Sales Volume Growth Rate (2017-2022)
3.6.2 South Asia Budesonide Inhaler Sales Volume Capacity, Revenue, Price and Gross Margin (2017-2022)
3.7 Southeast Asia Budesonide Inhaler Sales Volume (2017-2022)
3.7.1 Southeast Asia Budesonide Inhaler Sales Volume Growth Rate (2017-2022)
3.7.2 Southeast Asia Budesonide Inhaler Sales Volume Capacity, Revenue, Price and Gross Margin (2017-2022)
3.8 Middle East Budesonide Inhaler Sales Volume (2017-2022)
3.8.1 Middle East Budesonide Inhaler Sales Volume Growth Rate (2017-2022)
3.8.2 Middle East Budesonide Inhaler Sales Volume Capacity, Revenue, Price and Gross Margin (2017-2022)
3.9 Africa Budesonide Inhaler Sales Volume (2017-2022)
3.9.1 Africa Budesonide Inhaler Sales Volume Growth Rate (2017-2022)
3.9.2 Africa Budesonide Inhaler Sales Volume Capacity, Revenue, Price and Gross Margin (2017-2022)
3.10 Oceania Budesonide Inhaler Sales Volume (2017-2022)
3.10.1 Oceania Budesonide Inhaler Sales Volume Growth Rate (2017-2022)
3.10.2 Oceania Budesonide Inhaler Sales Volume Capacity, Revenue, Price and Gross Margin (2017-2022)
3.11 South America Budesonide Inhaler Sales Volume (2017-2022)
3.11.1 South America Budesonide Inhaler Sales Volume Growth Rate (2017-2022)
3.11.2 South America Budesonide Inhaler Sales Volume Capacity, Revenue, Price and Gross Margin (2017-2022)
3.12 Rest of the World Budesonide Inhaler Sales Volume (2017-2022)
3.12.1 Rest of the World Budesonide Inhaler Sales Volume Growth Rate (2017-2022)
3.12.2 Rest of the World Budesonide Inhaler Sales Volume Capacity, Revenue, Price and Gross Margin (2017-2022)
4 North America
4.1 North America Budesonide Inhaler Consumption by Countries
4.2 United States
4.3 Canada
4.4 Mexico
5 East Asia
5.1 East Asia Budesonide Inhaler Consumption by Countries
5.2 China
5.3 Japan
5.4 South Korea
6 Europe
6.1 Europe Budesonide Inhaler Consumption by Countries
6.2 Germany
6.3 United Kingdom
6.4 France
6.5 Italy
6.6 Russia
6.7 Spain
6.8 Netherlands
6.9 Switzerland
6.10 Poland
7 South Asia
7.1 South Asia Budesonide Inhaler Consumption by Countries
7.2 India
7.3 Pakistan
7.4 Bangladesh
8 Southeast Asia
8.1 Southeast Asia Budesonide Inhaler Consumption by Countries
8.2 Indonesia
8.3 Thailand
8.4 Singapore
8.5 Malaysia
8.6 Philippines
8.7 Vietnam
8.8 Myanmar
9 Middle East
9.1 Middle East Budesonide Inhaler Consumption by Countries
9.2 Turkey
9.3 Saudi Arabia
9.4 Iran
9.5 United Arab Emirates
9.6 Israel
9.7 Iraq
9.8 Qatar
9.9 Kuwait
9.10 Oman
10 Africa
10.1 Africa Budesonide Inhaler Consumption by Countries
10.2 Nigeria
10.3 South Africa
10.4 Egypt
10.5 Algeria
10.6 Morocco
11 Oceania
11.1 Oceania Budesonide Inhaler Consumption by Countries
11.2 Australia
11.3 New Zealand
12 South America
12.1 South America Budesonide Inhaler Consumption by Countries
12.2 Brazil
12.3 Argentina
12.4 Columbia
12.5 Chile
12.6 Venezuela
12.7 Peru
12.8 Puerto Rico
12.9 Ecuador
13 Rest of the World
13.1 Rest of the World Budesonide Inhaler Consumption by Countries
13.2 Kazakhstan
14 Sales Volume, Sales Revenue, Sales Price Trend by Type
14.1 Global Budesonide Inhaler Sales Volume Market Share by Type (2017-2022)
14.2 Global Budesonide Inhaler Sales Revenue Market Share by Type (2017-2022)
14.3 Global Budesonide Inhaler Sales Price by Type (2017-2022)
15 Consumption Analysis by Application
15.1 Global Budesonide Inhaler Consumption Volume by Application (2017-2022)
15.2 Global Budesonide Inhaler Consumption Value by Application (2017-2022)
16 Company Profiles and Key Figures in Budesonide Inhaler Business
16.1 AstraZeneca
16.1.1 AstraZeneca Company Profile
16.1.2 AstraZeneca Budesonide Inhaler Product Specification
16.1.3 AstraZeneca Budesonide Inhaler Production Capacity, Revenue, Price and Gross Margin (2017-2022)
16.2 Cosmo Pharmaceuticals
16.2.1 Cosmo Pharmaceuticals Company Profile
16.2.2 Cosmo Pharmaceuticals Budesonide Inhaler Product Specification
16.2.3 Cosmo Pharmaceuticals Budesonide Inhaler Production Capacity, Revenue, Price and Gross Margin (2017-2022)
16.3 Teva Pharmaceutical
16.3.1 Teva Pharmaceutical Company Profile
16.3.2 Teva Pharmaceutical Budesonide Inhaler Product Specification
16.3.3 Teva Pharmaceutical Budesonide Inhaler Production Capacity, Revenue, Price and Gross Margin (2017-2022)
16.4 Novartis
16.4.1 Novartis Company Profile
16.4.2 Novartis Budesonide Inhaler Product Specification
16.4.3 Novartis Budesonide Inhaler Production Capacity, Revenue, Price and Gross Margin (2017-2022)
16.5 Mylan
16.5.1 Mylan Company Profile
16.5.2 Mylan Budesonide Inhaler Product Specification
16.5.3 Mylan Budesonide Inhaler Production Capacity, Revenue, Price and Gross Margin (2017-2022)
16.6 Pfizer
16.6.1 Pfizer Company Profile
16.6.2 Pfizer Budesonide Inhaler Product Specification
16.6.3 Pfizer Budesonide Inhaler Production Capacity, Revenue, Price and Gross Margin (2017-2022)
16.7 Dr. Falk Pharma
16.7.1 Dr. Falk Pharma Company Profile
16.7.2 Dr. Falk Pharma Budesonide Inhaler Product Specification
16.7.3 Dr. Falk Pharma Budesonide Inhaler Production Capacity, Revenue, Price and Gross Margin (2017-2022)
16.8 Chiesi Farmaceutici
16.8.1 Chiesi Farmaceutici Company Profile
16.8.2 Chiesi Farmaceutici Budesonide Inhaler Product Specification
16.8.3 Chiesi Farmaceutici Budesonide Inhaler Production Capacity, Revenue, Price and Gross Margin (2017-2022)
16.9 Orion Corporation
16.9.1 Orion Corporation Company Profile
16.9.2 Orion Corporation Budesonide Inhaler Product Specification
16.9.3 Orion Corporation Budesonide Inhaler Production Capacity, Revenue, Price and Gross Margin (2017-2022)
16.10 Cipla Limited
16.10.1 Cipla Limited Company Profile
16.10.2 Cipla Limited Budesonide Inhaler Product Specification
16.10.3 Cipla Limited Budesonide Inhaler Production Capacity, Revenue, Price and Gross Margin (2017-2022)
16.11 Bausch Health Companies
16.11.1 Bausch Health Companies Company Profile
16.11.2 Bausch Health Companies Budesonide Inhaler Product Specification
16.11.3 Bausch Health Companies Budesonide Inhaler Production Capacity, Revenue, Price and Gross Margin (2017-2022)
16.12 Takeda Pharmaceutical
16.12.1 Takeda Pharmaceutical Company Profile
16.12.2 Takeda Pharmaceutical Budesonide Inhaler Product Specification
16.12.3 Takeda Pharmaceutical Budesonide Inhaler Production Capacity, Revenue, Price and Gross Margin (2017-2022)
16.13 Lupin Limited
16.13.1 Lupin Limited Company Profile
16.13.2 Lupin Limited Budesonide Inhaler Product Specification
16.13.3 Lupin Limited Budesonide Inhaler Production Capacity, Revenue, Price and Gross Margin (2017-2022)
16.14 Synmosa Biopharma Corporation
16.14.1 Synmosa Biopharma Corporation Company Profile
16.14.2 Synmosa Biopharma Corporation Budesonide Inhaler Product Specification
16.14.3 Synmosa Biopharma Corporation Budesonide Inhaler Production Capacity, Revenue, Price and Gross Margin (2017-2022)
16.15 Lunan Better Pharmaceutical
16.15.1 Lunan Better Pharmaceutical Company Profile
16.15.2 Lunan Better Pharmaceutical Budesonide Inhaler Product Specification
16.15.3 Lunan Better Pharmaceutical Budesonide Inhaler Production Capacity, Revenue, Price and Gross Margin (2017-2022)
16.16 Shanghai Sine Pharmaceutical Laboratories
16.16.1 Shanghai Sine Pharmaceutical Laboratories Company Profile
16.16.2 Shanghai Sine Pharmaceutical Laboratories Budesonide Inhaler Product Specification
16.16.3 Shanghai Sine Pharmaceutical Laboratories Budesonide Inhaler Production Capacity, Revenue, Price and Gross Margin (2017-2022)
17 Budesonide Inhaler Manufacturing Cost Analysis
17.1 Budesonide Inhaler Key Raw Materials Analysis
17.1.1 Key Raw Materials
17.2 Proportion of Manufacturing Cost Structure
17.3 Manufacturing Process Analysis of Budesonide Inhaler
17.4 Budesonide Inhaler Industrial Chain Analysis
18 Marketing Channel, Distributors and Customers
18.1 Marketing Channel
18.2 Budesonide Inhaler Distributors List
18.3 Budesonide Inhaler Customers
19 Market Dynamics
19.1 Market Trends
19.2 Opportunities and Drivers
19.3 Challenges
19.4 Porter's Five Forces Analysis
20 Production and Supply Forecast
20.1 Global Forecasted Production of Budesonide Inhaler (2023-2032)
20.2 Global Forecasted Revenue of Budesonide Inhaler (2023-2032)
20.3 Global Forecasted Price of Budesonide Inhaler (2017-2032)
20.4 Global Forecasted Production of Budesonide Inhaler by Region (2023-2032)
20.4.1 North America Budesonide Inhaler Production, Revenue Forecast (2023-2032)
20.4.2 East Asia Budesonide Inhaler Production, Revenue Forecast (2023-2032)
20.4.3 Europe Budesonide Inhaler Production, Revenue Forecast (2023-2032)
20.4.4 South Asia Budesonide Inhaler Production, Revenue Forecast (2023-2032)
20.4.5 Southeast Asia Budesonide Inhaler Production, Revenue Forecast (2023-2032)
20.4.6 Middle East Budesonide Inhaler Production, Revenue Forecast (2023-2032)
20.4.7 Africa Budesonide Inhaler Production, Revenue Forecast (2023-2032)
20.4.8 Oceania Budesonide Inhaler Production, Revenue Forecast (2023-2032)
20.4.9 South America Budesonide Inhaler Production, Revenue Forecast (2023-2032)
20.4.10 Rest of the World Budesonide Inhaler Production, Revenue Forecast (2023-2032)
20.5 Forecast by Type and by Application (2023-2032)
20.5.1 Global Sales Volume, Sales Revenue and Sales Price Forecast by Type (2023-2032)
20.5.2 Global Forecasted Consumption of Budesonide Inhaler by Application (2023-2032)
21 Consumption and Demand Forecast
21.1 North America Forecasted Consumption of Budesonide Inhaler by Country
21.2 East Asia Market Forecasted Consumption of Budesonide Inhaler by Country
21.3 Europe Market Forecasted Consumption of Budesonide Inhaler by Countriy
21.4 South Asia Forecasted Consumption of Budesonide Inhaler by Country
21.5 Southeast Asia Forecasted Consumption of Budesonide Inhaler by Country
21.6 Middle East Forecasted Consumption of Budesonide Inhaler by Country
21.7 Africa Forecasted Consumption of Budesonide Inhaler by Country
21.8 Oceania Forecasted Consumption of Budesonide Inhaler by Country
21.9 South America Forecasted Consumption of Budesonide Inhaler by Country
21.10 Rest of the world Forecasted Consumption of Budesonide Inhaler by Country
22 Research Findings and Conclusion
23 Methodology and Data Source
23.1 Methodology/Research Approach
23.1.1 Research Programs/Design
23.1.2 Market Size Estimation
23.1.3 Market Breakdown and Data Triangulation
23.2 Data Source
23.2.1 Secondary Sources
23.2.2 Primary Sources
23.3 Disclaimer
Quality Assurance Process
- We Market Research’s Quality Assurance program strives to deliver superior value to our clients.
We Market Research senior executive is assigned to each consulting engagement and works closely with the project team to deliver as per the clients expectations.
Market Research Process
We Market Research monitors 3 important attributes during the QA process- Cost, Schedule & Quality. We believe them as a critical benchmark in achieving a project’s success.
To mitigate risks that can impact project success, we deploy the follow project delivery best practices:
- Project kickoff meeting with client
- Conduct frequent client communications
- Form project steering committee
- Assign a senior SR executive as QA Executive
- Conduct internal editorial & quality reviews of project deliverables
- Certify project staff in SR methodologies & standards
- Monitor client satisfaction
- Monitor realized value post-project
Case Study- Automotive Sector
One of the key manufacturers of automotive had plans to invest in electric utility vehicles. The electric cars and associated markets being a of evolving nature, the automotive client approached Straits Research for a detailed insight on the market forecasts. The client specifically asked for competitive analysis, regulatory framework, regional prospects studied under the influence of drivers, challenges, opportunities, and pricing in terms of revenue and sales (million units).
Solution
The overall study was executed in three stages, intending to help the client meet its objective of precisely understanding the entire market before deciding on an investment. At first, secondary research was conducted considering political, economic, social, and technological parameters to get a gist of the various aspects of the market. This stage of the study concluded with the derivation of drivers, opportunities, and challenges. It also laid substantial emphasis on understanding and collecting data not only on a global scale but also on the regional and country levels. Data Extraction through Primary Research
The second stage involved primary research in which several market players and automotive parts suppliers were contacted to study their viewpoint concerning the development of their market and production capacity, clientele, and product line. This stage concluded in a brief understanding of the competitive ecosystem and also glanced through the strategies and pricing of the companies profiled.
Market Estimates and Forecast
In the final stage of the study, market forecasts for the electric utility were derived using multiple market engineering approaches. This data helped the client to get an overview of the market and accelerate the process of investment.
Case Study- ICT Sector
Business process outsourcing, being one of the lucrative markets from both supply- and demand- side, has appealed to various companies. One of the prominent corporations based out of Japan approached us with their requirements regarding the scope of the procurement outsourcing market for around 50 countries. Additionally, the client also sought key players operating in the market and their revenue breakdown in terms of region and application.
Business Solution
An exhaustive market study was conducted based on primary and secondary research that involved factors such as labor costs in various countries, skilled and technical labors, manufacturing scenario, and their respective contributions in the global GDP. A comparative study of the market was conducted from both supply- and demand side, with the supply-side comprising of notable companies, such as GEP, Accenture, and others, that provide these services. On the other hand, large manufacturing companies from them demand-side were considered that opt for these services.
Conclusion
The report aided the client in understanding the market trends, including country-level business scenarios, consumer behavior, and trends in 50 countries. The report also provided financial insights of crucial players and detailed market estimations and forecasts till 2028.
}})
Select a license type that suits your business needs
US $3950
Only Three Thousand Nine Hundred Fifty US dollar
- 1 User access
- 15% Additional Free Customization
- Free Unlimited post-sale support
- 100% Service Guarantee until achievement of ROI
US $4950
Only Four Thousand Nine Hundred Fifty US dollar
- 5 Users access
- 25% Additional Free Customization
- Access Report summaries for Free
- Guaranteed service
- Dedicated Account Manager
- Discount of 20% on next purchase
- Get personalized market brief from Lead Author
- Printing of Report permitted
- Discount of 20% on next purchase
- 100% Service Guarantee until achievement of ROI
US $5950
Only Five Thousand Nine Hundred Fifty US dollar
- Unlimited User Access
- 30% Additional Free Customization
- Exclusive Previews to latest or upcoming reports
- Discount of 30% on next purchase
- 100% Service Guarantee until achievement of ROI